Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ComPAKT: Olaparib and AZD5363 in Advanced Solid Tumors
NCT02338622Phase 1Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Mar 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaparib and capivasertib in solid tumor (advanced stage), triple negative breast cancer (TNBC), prostate cancer (PCa) and 1 more (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Safety and tolerability of olaparib in combination with AZD5363 and Maximum Tolerated Dose and Recommended Phase II Dose. Started Mar 2014; status: completed.
02
Drugs
olaparibcapivasertib
03
Conditions
solid tumor (advanced stage)triple negative breast cancer (TNBC)prostate cancer (PCa)High-Grade Serous Ovarian Carcinoma (HGSOC)
Beyond the preview
Go deeper on NCT02338622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338622.